The AstraZeneca drug corporation launched its first clinical pharmacology unit in the United States at Penn's Presbyterian Medical Center yesterday, according to the company.
A clinical pharmacology unit conducts research about the safety of developing drugs and performs initial human testing.
The unit's opening comes just six months after AstraZeneca entered a research partnership with Penn's Health System, aimed at allowing both parties to develop drugs more efficiently.
AstraZeneca, which is based in London, operates four other clinical pharmacology units in the United Kingdom and Sweden.
The University already has research partnerships with over 200 corporations, Penn Director of Corporate Alliances Terry Fadem said earlier this year.
The Daily Pennsylvanian is an independent, student-run newspaper. Please consider making a donation to support the coverage that shapes the University. Your generosity ensures a future of strong journalism at Penn.
DonatePlease note All comments are eligible for publication in The Daily Pennsylvanian.